Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Total Non-Current Liabilities (2016 - 2025)

AC Immune (ACIU) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 9.67% to $18.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.4 million through Dec 2025, down 9.67% year-over-year, with the annual reading at $18.4 million for FY2025, 9.67% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $18.4 million at AC Immune, down from $20.3 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $20.3 million in Q4 2024, with the low at $5.7 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $12.9 million, with a median of $10.2 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities tumbled 44.57% in 2022, then soared 109.76% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $10.2 million in 2021, then crashed by 44.57% to $5.7 million in 2022, then skyrocketed by 70.78% to $9.7 million in 2023, then surged by 109.76% to $20.3 million in 2024, then decreased by 9.67% to $18.4 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $18.4 million, $20.3 million, and $9.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.